Teraliv 275
Teraliv 275: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Use in childhood
- 11. In case of impaired renal function
- 12. For violations of liver function
- 13. Use in the elderly
- 14. Drug interactions
- 15. Analogs
- 16. Terms and conditions of storage
- 17. Terms of dispensing from pharmacies
- 18. Reviews
- 19. Price in pharmacies
Latin name: Teralive 275
ATX code: M01AE02; M02AA12
Active ingredient: naproxen (Naproxen)
Manufacturer: Bayer Bitterfeld, GmbH (Germany)
Description and photo update: 2020-06-02
Prices in pharmacies: from 125 rubles.
Buy
Teraliv 275 - NSAIDs (non-steroidal anti-inflammatory drug) with antipyretic, analgesic and anti-inflammatory effects. It has an effect directly on the specific mechanisms of joint pain, contributes to its relief up to 12 hours.
Release form and composition
The drug is produced in the form of film-coated tablets: biconvex, oval, engraved on one side in the form of the inscription "NPS-275"; the film shell is blue, the core at the fracture is white (in blisters made of polyvinyl chloride film and aluminum, 12 tablets each, in a cardboard box of 1 or 2 blisters and instructions for use of Teraliv 275).
One tablet contains:
- active ingredient: sodium naproxen - 275 mg;
- additional ingredients: MCC (microcrystalline cellulose) - 55 mg; talc - 15.75 mg; povidone K-30 - 12.5 mg; magnesium stearate - 2.63 mg;
- composition of the film shell: Opadrai blue YS-1-4215 (hypromellose, indigo carmine, titanium dioxide, macrogol 8000) - 9 mg.
Pharmacological properties
Pharmacodynamics
The active substance of Teraliv 275 is naproxen, which has antipyretic, analgesic and anti-inflammatory properties. The mechanism of action of NSAIDs is associated with non-selective inhibition of the activity of COX-1 and COX-2 (cyclooxygenase-1 and cyclooxygenase-2).
The drug dissolves well in the gastrointestinal tract (gastrointestinal tract), from where it is immediately absorbed and provides a rapid onset of the analgesic effect.
Pharmacokinetics
Naproxen is rapidly and fully absorbed from the gastrointestinal tract. Bioavailability is 95% (while food intake does not significantly affect the rate and completeness of absorption). T Cmax (time to reach maximum concentration) - 1–2 hours. The connection with blood plasma proteins is above 99%.
With the participation of the CUR2C9 isoenzyme, naproxen is metabolized in the liver to dimethylnaproxen. The clearance is 0.13 ml / min / kg.
T 1/2 (half-life) is 12-15 hours. Naproxen is excreted in urine (98%, of which 10% unchanged) and bile (0.5-2.5%). The equilibrium concentration in blood plasma can be determined after taking four to five doses of Teraliv 275 (two to three days).
In patients with renal insufficiency, there is a risk of accumulation of metabolites.
Indications for use
Teraliv 275 tablets are used in the following cases:
- pain syndrome of weak or moderate severity: toothache / headache, migraine, algomenorrhea, lumboischialgia, ossalgia, neuralgia, myalgia; post-traumatic pain syndrome (bruises, sprains), accompanied by inflammation;
- diseases of the musculoskeletal system: osteoarthritis of the peripheral joints and spine (including those with radicular syndrome), bursitis, tendovaginitis, rheumatic lesions of soft tissues;
- febrile syndrome with colds and infectious diseases;
- diseases of the ear, throat, nose of an infectious and inflammatory nature with severe pain syndrome: otitis media, tonsillitis, pharyngitis - as part of complex therapy.
Teraliv 275 is used for symptomatic therapy in order to reduce fever, pain and inflammation. Taking pills does not affect the progression of the underlying disease.
Contraindications
Absolute:
- hemostasis disorders and blood clotting disorders (including hemophilia);
- bleeding from the gastrointestinal tract in the active phase, erosive and ulcerative lesions of the gastric mucosa or duodenum;
- bleeding (including cerebrovascular);
- inflammatory bowel diseases (Crohn's disease, ulcerative colitis) in the acute phase;
- confirmed hyperkalemia, progressive kidney disease, severe renal failure with CC (creatinine clearance) not more than 30 ml / min;
- period after coronary artery bypass grafting;
- heart failure in the phase of decompensation;
- active liver disease or severe liver failure;
- complete / incomplete combination of bronchial asthma with recurrent polyposis of the nose or paranasal sinuses and intolerance to acetylsalicylic acid, and other NSAIDs (including history);
- children under 15 years of age;
- period of pregnancy and lactation;
- hypersensitivity to naproxen or naproxen sodium.
Relative (in the presence of the following diseases / conditions, use Teraliv 275 tablets with extreme caution):
- Ischemic heart disease (ischemic heart disease), congestive heart failure;
- cerebrovascular diseases;
- peripheral arterial disease;
- hyperlipidemia, dyslipidemia;
- impaired renal function with CC from 30 to 60 ml / min;
- presence of Helicobacter pylori infection;
- a history of data on the development of ulcerative lesions of the gastrointestinal tract;
- SLE (systemic lupus erythematosus) or Sharpe syndrome (mixed connective tissue diseases);
- diabetes;
- smoking;
- alcohol abuse;
- long-term use of NSAIDs;
- elderly age;
- severe somatic diseases;
- combined administration with anticoagulants (for example, warfarin), antiplatelet agents (for example, clopidogrel, acetylsalicylic acid), oral glucocorticoids (for example, prednisolone), selective serotonin reuptake inhibitors (for example, fluoxetine, serotralinom), paroxetine, paroxetine
Teraliv 275, instructions for use: method and dosage
Teraliv 275 tablets are taken orally with a sufficient amount of liquid.
The drug is prescribed for adults and adolescents over 15 years of age:
- as an anesthetic: the usual dose is 2-3 tablets (550-825 mg) per day, the course of administration is no more than 5 days. The maximum allowable dose is 3 tablets (825 mg) per day; to relieve menstrual cramps and cramps, pain after the introduction of the IUD (intrauterine devices) and other gynecological pains, Teraliv 275 is taken every 8 hours, first 2 tablets (550 mg), and then 1 tablet (275 mg); in order to prevent and relieve migraine attacks, first take 2 tablets (further, if necessary, the dose can be reduced to 1 tablet) every 8-12 hours;
- as an antipyretic: the initial dose is 2 tablets every 8 hours, then a single dose is reduced to 1 tablet while maintaining an 8-hour interval.
Elderly patients (over the age of 65) take Teraliv 275 as needed, observing a 12-hour interval between pills.
To reduce the risk of adverse reactions from the digestive system, it is necessary to take Teraliv 275 tablets in the minimum effective dose for the shortest possible course.
If there is a suspicion of a very strong or, conversely, a very weak effect of Teraliv 275, you should inform your doctor about it.
Side effects
During naproxen therapy, the following systemic and organ side effects may develop [classified according to the following frequency of occurrence: very common (> 1/10); often (from ≥ 1/100 to <1/10); infrequently (from ≥ 1/1000 to <1/100); rarely (from ≥ 1/10 000 to <1/1000); extremely rare (<1/10 000); frequency not determined (it is impossible to establish the frequency of occurrence of adverse reactions based on the available data)]:
- blood and lymphatic system: infrequently - leukopenia, eosinophilia, thrombocytopenia, granulocytopenia;
- nervous system: often - drowsiness, dizziness, vertigo, headache; infrequently - malaise, insomnia, sleep disturbances, inability to concentrate, depression;
- organ of vision: often - visual impairment;
- organ of hearing and labyrinth disorders: often - hearing impairment, tinnitus; infrequently - hearing loss;
- cardiovascular system: often - palpitations, swelling; infrequently - congestive heart failure;
- respiratory system, organs of the chest and mediastinum: often - shortness of breath; infrequently - eosinophilic pneumonia;
- digestive system: often - nausea, abdominal pain, diarrhea, constipation, flatulence, dyspepsia, stomatitis; infrequently - bleeding from the gastrointestinal tract and / or perforation of the stomach, melena, vomiting / bloody vomiting; extremely rare - relapse or exacerbation of ulcerative colitis / Crohn's disease; frequency not determined - gastritis;
- liver and biliary tract: infrequently - jaundice, increased activity of liver enzymes;
- skin and subcutaneous tissues: often - ecchymosis, skin rash, pruritus, purpura; infrequently - photodermatosis, alopecia; extremely rarely - bullous reactions (including Lyell and Stevens-Johnson syndromes);
- musculoskeletal and connective tissue: infrequently - muscle weakness, myalgia;
- urinary system: infrequently - renal papillary necrosis, renal failure, interstitial nephritis, glomerulonephritis, nephrotic syndrome, hematuria;
- general disorders: often - increased sweating, thirst; infrequently - menstrual irregularities, hypersensitivity reactions, hyperthermia (fever and chills).
The most common side reactions were from the digestive system. Cases of development of peptic ulcers, perforation and bleeding from the gastrointestinal tract, in some cases with a lethal outcome, especially in elderly patients, are not excluded.
There are reports that the use of NSAIDs was accompanied by an increase in blood pressure (blood pressure), the appearance of edema and symptoms of heart failure.
Clinical trials have shown that the use of some NSAIDs (especially long-term therapy and high doses) may increase the risk of arterial thrombosis (for example, stroke / myocardial infarction).
Side effects for which a causal relationship with the use of naproxen could not be established:
- blood and lymphatic system: hemolytic anemia, aplastic anemia;
- nervous system: cognitive dysfunction, aseptic meningitis;
- skin and subcutaneous tissues: erythema multiforme, urticaria, photosensitivity reactions similar to the manifestations of porphyria cutaneous tarda and epidermolysis bullosa;
- vessels: vasculitis;
- general disorders: hypoglycemia, hyperglycemia, angioedema.
If you notice the development of the above or other side effects not listed in this instruction, you should consult your doctor.
Overdose
With a significant overdose of Teraliv 275, the following symptoms may occur: weakness, drowsiness, irritability, tinnitus, dyspeptic disorders (abdominal pain, nausea / vomiting, heartburn), in severe cases - renal failure, impaired consciousness, melena, bloody vomiting, convulsions …
As a treatment, a patient who intentionally or accidentally took a large number of Teraliv 275 tablets is given gastric lavage and activated charcoal to drink. In the future, symptomatic therapy is carried out - proton pump inhibitors, blockers of H 2 receptors, antacids are prescribed. Hemodialysis with an overdose of naproxen is ineffective.
special instructions
It is impossible to exceed the doses of NSAIDs recommended in this instruction. To reduce the risk of developing side effects from the digestive system, it is necessary to take the agent in the minimum effective doses for the shortest possible course.
If pain and febrile syndromes persist or worsen, it is necessary to seek medical help. If the patient is diagnosed with bronchial asthma, bleeding disorders or hypersensitivity to other analgesics, you should consult a specialist before starting the drug.
Teraliv 275 tablets are prescribed with caution in patients with renal failure and liver disease. It is important for patients with impaired renal function to control creatinine clearance (CC). If the CC is less than 30 ml / min, it is not recommended to use naproxen. With cirrhosis of the liver (chronic alcoholic or other etiological forms of cirrhosis of the liver), the concentration of unbound naproxen increases; therefore, patients with this diagnosis should take the drug in lower doses. After a two-week period of treatment, liver function indicators should be monitored.
Teraliv 275 is not recommended to be combined with other analgesic and anti-inflammatory drugs, unless otherwise prescribed by a doctor.
Elderly patients (over the age of 65) are also recommended to use the agent in lower doses.
Do not take naproxen within 2 days of surgery.
If it is necessary to determine 17-corticosteroids, it is necessary to stop taking the drug two days before the study. Similarly, naproxen may interfere with the determination of 5-hydroxyindoleacetic acid in urine.
Naproxen, like other drugs that block prostaglandin synthesis, can affect fertility, so Teraliv 275 is not recommended for women planning a pregnancy.
Each tablet contains approximately 25 mg sodium. This is important to consider for those who limit salt intake.
Influence on the ability to drive vehicles and complex mechanisms
Naproxen slows down the reaction rate in humans. In addition, dizziness and drowsiness can be side effects from taking the drug. In view of the above, patients taking Teraliv 275 should be careful when driving vehicles and activities that require increased concentration.
Application during pregnancy and lactation
Pregnant and breastfeeding women should not take Teraliv 275.
Pediatric use
Teraliv 275 is contraindicated in children and adolescents under 15 years of age.
Adolescents over 15 years of age take NSAIDs in doses prescribed for adult patients.
With impaired renal function
With progressive kidney disease or severe renal failure (CC less than 30 ml / min), the drug is contraindicated.
In case of impaired renal function with QC from 30 to 60 ml / min, Teraliv 275 tablets are used with caution.
For violations of liver function
Active liver disease and severe liver failure are contraindications to taking Teraliv 275 tablets.
Use in the elderly
Elderly patients (over 65 years of age) should be careful when taking NSAIDs.
Drug interactions
- acetylsalicylic acid, other NSAIDs, including selective COX-2 inhibitors: the risk of unwanted side reactions (including gastrointestinal bleeding) increases;
- anticoagulants (including warfarin): when taken in combination with anticoagulants, naproxen can increase bleeding time; also NSAIDs can enhance the effect of anticoagulants, for example, warfarin;
- hydantoins, anticoagulants or other drugs that largely bind to plasma proteins: potentiation of the action or overdose of these drugs is possible;
- ACE inhibitors (angiotensin-converting enzyme): the risk of developing renal failure increases;
- diuretics (including furosemide): it is possible to reduce the diuretic effect of diuretics. In turn, the latter are capable of increasing the risk of NSAID nephrotoxicity. Under the influence of naproxen, the natriuretic effect of furosemide is inhibited;
- propranolol and other β-blockers: a decrease in the antihypertensive effect is possible;
- lithium: the renal clearance of lithium is inhibited, which leads to an increase in the concentration of this substance in the blood plasma;
- corticosteroids: a possible increase in the risk of ulceration or bleeding from the gastrointestinal tract;
- sulfonamides, methotrexate, phenytoin: naproxen slows down their excretion, which increases the risk of developing toxic effects;
- probenecid: increases the concentration of naproxen in blood plasma;
- myelotoxic drugs: while taking the drug, the manifestations of hematotoxicity are enhanced;
- cyclosporine: increases the risk of developing renal failure;
- antacids containing aluminum and magnesium: reduce the absorption of naproxen from the gastrointestinal tract;
- zidovudine: combined administration with naproxen increases the plasma concentration of zidovudine (according to in vitro studies);
- mifepristone: naproxen should not be taken at the same time as mifepristone and for 8-12 days after the antigestagenic drug is used;
- tacrolimus: when taken together, the risk of nephrotoxicity increases.
Analogs
The analogues of Teraliv 275 are Pentalgin Mono, Niaproff, Nalgezin, Nalgezin Forte, Motrin, Algezir Ultra, etc.
Terms and conditions of storage
Store out of the reach of children, in compliance with the temperature regime (no more than 25 ° C).
The shelf life is 5 years.
After the expiration date, the drug must not be used.
Terms of dispensing from pharmacies
Available without a prescription.
Reviews about Teraliva 275
In general, there are positive reviews about Teraliva 275 on the Internet. Among the advantages of the drug, patients note a wide spectrum of action of NSAIDs, high efficiency, affordable cost, convenient form of tablets, due to which there are no difficulties with swallowing. It is noted that the drug relieves pain, helps with renal colic, with acute pain it acts for five to six hours, does not have an aggressive effect on the gastrointestinal tract, unlike similar drugs.
In some reviews, some patients claim that the remedy does not help right away, others complain about the lack of any effect. The disadvantages of Teraliv 275 are considered the presence of a large list of side effects, the inability to use in children under 15 years of age, as well as the discrepancy between the real time of the anesthetic action and the expected one (it does not work for 12 hours, but less).
Price for Teraliv 275 in pharmacies
The price of Teraliv 275, film-coated tablets, 275 mg, in pharmacy chains is: per pack of 12 pcs. - 114–234 rubles, per pack of 24 pcs. - 208-299 rubles.
Teraliv 275: prices in online pharmacies
|
Drug name Price Pharmacy |
|
Teraliv 275 mg film-coated tablets 12 pcs. 125 RUB Buy |
|
Teraliv 275 tablets p.o. 275mg 12 pcs. 143 r Buy |
|
Teraliv 275 mg film-coated tablets 24 pcs. 208 RUB Buy |
|
Teraliv 275 tablets p.o. 275mg 24 pcs. 226 r Buy |
Anna Kozlova Medical journalist About the author
Education: Rostov State Medical University, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
